TP53 and breast adenocarcinoma: In order to investigate metabolic requirements of cells that evade chemotherapy-induced senescence, we treated with sublethal concentrations of doxorubicin two wild-type p53-positive cancer cell line, MCF-7 (breast adenocarcinoma) and A549 (lung adenocarcinoma).